Corbus Pharmaceuticals Announces Presentation of Six

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
132
Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

NORWOOD, MA --(Marketwired - September 20, 2017) - Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology ("ACR") 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California.

Summarized below are the abstract titles that have been selected for oral or poster presentations. The ACR abstracts are available online at the conference website . Information from the ACR presentations are under embargo until November 4, 2017 at 4:30 PM PDT. Once the posters are made public, they will be available on the Company's website in the Presentations section.

Sunday, November 5, 2017

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I Time: 9:00 - 11:00 AM PDT Presenter: Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City and Principal Investigator of the Phase 2 study in systemic sclerosis Abstract #725: Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in An Open-Label Extension of Trial JBT101-SSc-001

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I Time: 9:00 - 11:00 AM PDT Presenter: Barbara White, M.D., Chief Medical Officer of Corbus Abstract #738: Prospective Validation of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Session: Innate Immunity and Rheumatic Disease Poster I Time: 9:00 - 11:00 AM PDT Presenter: Mark A. Tepper, Ph.D., Chief Scientific Officer of Corbus Abstract #298: Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans

Monday, November 6, 2017

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II Time: 9:00 - 11:00 AM PDT Presenter: Viktor Martyanov, Ph.D., Research Scientist at the Geisel School of Medicine at Dartmouth, Department of Molecular and Systems Biology Abstract #1707: Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial

Tuesday, November 7, 2017

Session: Muscle Biology, Myositis and Myopathies Poster Time: 9:00 - 11:00 AM PDT Presenter: Victoria Werth, M.D., Professor of Dermatology and Medicine at the University of Pennsylvania School of Medicine and Principal Investigator of Corbus' Phase 2 study in Dermatomyositis Abstract #2156: Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist

Session: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics II Time: 4:30 - 6:00 PM PDT Presenter: Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City and Principal Investigator of the Phase 2 study in systemic sclerosis Abstract #2884: A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist in Diffuse Cutaneous Systemic Sclerosis

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and human clinical studies have shown anabasum to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis and cystic fibrosis, respectively. The Company also expects to report data from its Phase 2 study of anabasum in skin predominant dermatomyositis in the fourth quarter of 2017. Additionally, anabasum is being evaluated in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis, and in a Phase 2 study in systemic lupus erythematosus expected to commence in the fourth quarter of 2017.

Corbus plans to commence a Phase 3 study of anabasum for the treatment of systemic sclerosis in the fourth quarter of 2017. The Company is also planning to initiate a Phase 2b study of anabasum for the treatment of cystic fibrosis in the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts Jenene Thomas Jenene Thomas Communications, LLC Phone: (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact Nic DiBella JPA Health Communications Phone: (617) 657-1307 Email: Nic@jpa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 77

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 135

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Cooperate Marketing Lands 318th on Deloitte Fast 500

Updated Category News Views 30

A 199% revenue jump over three years will get my attention before any shiny award logo does. Cooperate Marketing says it grew that much from 2022 through 2025, enough to place No. 318 on Deloitte's 2026 Technology Fast 500 list. For a privately held Chicago marketing-technology outfit, that is a legitimate operating milestone, not just another ribbon to pin on the company...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 53

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 163

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 113

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
Dario’s Second Women’s Health Win Tests Expansion Case

Updated Category News Views 89

Midlife care just became the newest proving ground for DarioHealth’s sales pitch. The company says The Minnesota Star Tribune has expanded its existing relationship to include Dario Women™, a program for employees navigating perimenopause and menopause. Eligible employees are expected to gain access in January 2027. For NASDAQ:DRIO, this is not some grand revenue...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 75

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Childcare Salary Guide Shows Shifts in Employment Trends

Updated Category News Views 311

Wage Trends in Childcare: A New Era Unfolds The landscape of childcare in America is morphing before our eyes, driven by economic forces and a changing workforce. With Crunch Care releasing its 2026 Childcare Salary Guide, we’re finally getting a clear picture of where wages and demand are headed, and it’s anything but static. Charting the Course of Childcare Wages...

Continue Reading
Sapiens Set to Reveal Q1 2025 Financial Insights Soon

Updated Category News Views 179

Sapiens International Corporation Announces Q1 2025 Financial Results Sapiens International Corporation (NASDAQ: SPNS) operates as a leading provider of software solutions specifically designed for the insurance sector. The company is preparing to unveil its financial outcomes for the first quarter of 2025. This significant announcement is scheduled for a date in early...

Continue Reading
Innovative Mobility Facility Unveiled at Kaweah Health

Updated Category News Views 225

Maison Law Launches Innovative Mobility Training Facility The "Maison Law Mobility Training Course at Kaweah Health" is a groundbreaking initiative that significantly improves the rehab journey for patients. This unique facility, the first of its kind in the area, is aimed at providing essential resources that empower patients to overcome their rehabilitation challenges...

Continue Reading
Aarki Unveils Encore: Revolutionizing Mobile Marketing Growth

Updated Category News Views 195

Aarki Unveils Encore: Revolutionizing Mobile Marketing Growth Encore is a groundbreaking platform that unifies User Acquisition and Retargeting through advanced machine learning, catering to the needs of mobile marketers grappling with strict privacy norms. By enhancing performance on both iOS and Android, Encore leverages deep neural network optimization to foster...

Continue Reading
BiomX's BX211 Shows Efficacy in Treating Diabetic Foot Issues

Updated Category News Views 235

Promising Phase 2 Trial Results for BX211 BiomX Inc. (NYSE American: PHGE), a pioneering clinical-stage company, recently revealed impressive topline results from its Phase 2 trial examining BX211 for diabetic foot osteomyelitis (DFO). This trial focused on individuals suffering from infections linked to Staphylococcus aureus, a bacteria known to complicate diabetic...

Continue Reading